Image

Nitric oxide Inhibition

ARTICLE:Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

AUTHORS: Dong I. Lee, Guangshuo Zhu, Takashi Sasaki, Gun-Sik Cho, Nazha Hamdani, Ronald Holewinski, Su-Hyun Jo, Thomas Danner, Manling Zhang, Peter P. Rainer, Djahida Bedja, Jonathan A. Kirk, Mark J. Ranek, Wolfgang R. Dostmann, Chulan Kwon, Kenneth B. Margulies, Jennifer E. Van Eyk, Walter J. Paulus, Eiki Takimoto, David A. Kass

JOURNAL: Nature. 2015 Mar 26;519(7544):472-6. doi: 10.1038/nature14332. Epub 2015 Mar 18

Abstract

Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease. However, cGMP stimulation alone is limited by counter-adaptions including PDE upregulation. Furthermore, although PDE5A regulates nitric-oxide-generated cGMP, nitric oxide signalling is often depressed by heart disease. PDEs controlling natriuretic-peptide-coupled cGMP remain uncertain. Here we show that cGMP-selective PDE9A (refs 7, 8) is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure. PDE9A regulates natriuretic-peptide- rather than nitric-oxide-stimulated cGMP in heart myocytes and muscle, and its genetic or selective pharmacological inhibition protects against pathological responses to neurohormones, and sustained pressure-overload stress. PDE9A inhibition reverses pre-established heart disease independent of nitric oxide synthase (NOS) activity, whereas PDE5A inhibition requires active NOS. Transcription factor activation and phosphoproteome analyses of myocytes with each PDE selectively inhibited reveals substantial differential targeting, with phosphorylation changes from PDE5A inhibition being more sensitive to NOS activation. Thus, unlike PDE5A, PDE9A can regulate cGMP signalling independent of the nitric oxide pathway, and its role in stress-induced heart disease suggests potential as a therapeutic target.

Read electro-mechanical engineering blog
You might also like
NO2-X (120 Capsules): Best Nitric Oxide & L-Arginine
NO2-X (120 Capsules): Best Nitric Oxide & L-Arginine ...
ALL About Nitric Oxide and the Pump!
ALL About Nitric Oxide and the Pump!
What is Nitric Oxide? - Dr. Thomas Burke
What is Nitric Oxide? - Dr. Thomas Burke
Nitric Oxide - Discover Why Qivana Prime Activator Is So
Nitric Oxide - Discover Why Qivana Prime Activator Is So ...
Qivana PRIME Nitric Oxide Activator Ingredients
Qivana PRIME Nitric Oxide Activator Ingredients
Ingredients Nitric Oxide Argenine and Citraline Plant
Ingredients Nitric Oxide Argenine and Citraline Plant ...
United States Biological Nitric Oxide Synthase, Brain (1-181) NOS1 (NOS, bNOS, nNOS, IHPS1, N-NOS, NC-NOS, Neuronal NOS, Peptidyl-cysteine S-nitrosylase NOS1), 144968-100ug
BISS (United States Biological)
  • Mab
  • Recognizes human, rat, goat and porcine Nitric Oxide Synthase, Brain (1-181), alpha. No cross reactivity with other proteins.
  • Ascites, supplied as a lyophilized powder. Reconstitution: 1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100ug/ml.
Source Naturals Source Naturals Inflama-Rest, 90 Tablets
Health and Beauty (Source Naturals)
  • Addresses multiple body systems shown to influence muscle and joint comfort
  • Formulated with adaptogenic herbs and minerals which may help reduce muscle tension
  • Helps protect cells from free radical damage
  • Supports comfortable movement via inhibition of the COX-2 enzyme
Related Posts